Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin

Pharmacotherapy

Volumn 19, Issue 4 I, 1999, Pages 404-415

  McConnell, Scott A ^a   Amsden, Guy W ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Bassett Hlthcare Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTACID AGENT; BROMOCRIPTINE; CARBAMAZEPINE; CIMETIDINE; CISAPRIDE; CLARITHROMYCIN; CYCLOSPORIN; DIDANOSINE; DIGOXIN; DIRITHROMYCIN; DISOPYRAMIDE; ERGOT ALKALOID; ERYTHROMYCIN; FLUCONAZOLE; LEVODOPA; LORATADINE; METHYLPREDNISOLONE; MEVINOLIN; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PHENAZONE; PHENYTOIN; RITONAVIR; TERFENADINE; THEOPHYLLINE; TRIAZOLAM; UNINDEXED DRUG; WARFARIN; ZIDOVUDINE;

ALLERGIC REACTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG INDICATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; OTOTOXICITY; RESPIRATORY TRACT INFECTION; REVIEW;

EID: 0032904979     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.6.404.31054     Document Type: Review

References (181)

1. McGuire JM, Bunch RL, Anderson RC, et al. Ilotycin, a new antibiotic. Antibiot Chemother 1952;2:281-3.
2. Mazzei T, Mini E, Novelli A, Periti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother 1993;31(suppl C):1-10.
3. Brock TD, Brock ML. Similarity in the mode of action of chloramphenicol and erythromycin. Biochim Biophys Acta 1959;240:245-6.
4. Fernandez-Munos R, Mouro RE, Torres-Pinedo R, Vasquez D. Substrate and antibiotic binding sites at peptidyl-transferase centre of Escherichia coli ribosomes. Studies on the chloramphenicol, linomycin, and erythromycin sites. Eur J Biochem 1971;23:185-93
5. Menniger JR, Otto DP. Erythromycin, cabomycin, and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes. Antimicrob Agents Chemother 1982;21:811-18.
6. Vasquez D. Inhibitors of protein synthesis. Fed Eur Biochem Soc Let 1979;40(suppl):S63-84.
7. Fernandez PB, Hardy DJ. Comparative in vitro potencies of nine new macrolides. Drug Exp Clin Res 1988;14:445-51.
8. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992;11:137-52.
9. Sides GD, Cerimele BJ, Black HR, Busch U, DeSante KA. Pharmacokinetics of dirithromycin. J Antimicrob Chemother 1993;31(suppl C):65-75.
10. Black HR, Brier GL, Wolny JD, DeSante KA. Dirithromycin: safety and tolerance of 500 mg daily vs erythromycin base 250 mg QID for 21 days [abstr]. In: Program and abstracts of the 29th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1989.
11. LaBrecque D , Johlin F, Janda R, et al. Pharmacokinetics of dirithromycin in patients with impaired hepatic function. J Antimicrob Chemother 1993;32:741-50.
12. Hand WL, Hand DL. Interactions of dirithromycin with human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1993;37(12):2557-62.
13. Varanese L. Pharmacokinetics and safety of dirithromycin in the elderly. J Antimicrob Chemother 1993;31(suppl C):169-74.
14. Goldberg MJ, Ring B, DeSante K, et al. Effect of dirithromycin on human CYP3A in vitro and on the pharmacokinetics of terfenadine in vivo. J Clin Pharmacol 1996;36:1154-60.
15. LaBrecque DR , Geraets D, Johlin FC, Lanier TL, Sides DG. Biliary elimination of dirithromycin after single-dose administration [abstr]. In: Program and abstracts of the 32nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1992.
16. Bozler G, Heinzel G, Lechner U, Schumacher K, Busch U. Pharmacokinetic properties and metabolic behavior of dirithromycin determine its high tissue penetration in man [abstr]. In: Program and abstracts of the 28th interscience conference on antimicrobial agents and chemotherapy Washington, DC: American Society for Microbiology, 1988.
17. Kisicki J, Smith R, DeSante K, Sides G. Pharmacokinetics of dirithromycin in the elderly population [abstr]. In: Program and abstracts of the 32nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1992.
18. Mazzei T, Surrenti C, Novelli A, et al. Single dose pharmacokinetics in patients with impaired hepatic function [abstr]. In: Program and abstracts of the 33rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1993.
19. Ripley ED, Sica DA, Gehr TW, Marshall C, Kish CW. Dirithromycin (D) pharmacokinetics (PK) in hemodialysis (HD) and chronic renal failure (CRF) [abstr]. Clin Pharmacol Ther 1992;51:137.
20. Abbott Laboratories. Clarithromycin prescribing information. North Chicago, IL;1996.
21. Peters DH, Clissold SP. Clarithromycin; a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992;44:117-64.
22. Chu S-Y, Deaton R, Cavanaugh J. Absolute bioavailabilily of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 1992;36:1147-50.
23. Chu S-Y, Park Y, Locke C, Wilson DS, Cavanaugh JC. Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 1992;32:32-6.
24. Chu S-Y, Wilson DS, Deaton RL, Mackenthun AV, Eason CN, Cavanaugh JH. Single- and multiple dose pharmacokinctics of clarithromycin after oral administration in humans. J Clin Pharmacol 1992;33:719-26.
25. Ishiguro M, Koga H, Hohno S, Hayashi T, Yamaguchi K, Hirota M. Penetration of macrolides into human polymorphonuclear leukocytes. J Antimicrob Chemother 1989;24:719-29.
26. Ballow CH, Amsden GW, Forrest A, Anderson AC. Comparison of the plasma urine and blister fluid pharmacokinetics of clarithromycin (C) and azithromycin (A) in normal subjects [abstr]. In: Program and abstracts of the 34th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1994.
27. Ferrero JL, Bopp BA, Marsh KC, et al. Metabolism and disposition of clarithromycin in man. Drug Metab Dispos 1990;18:441-6.
28. Davey PG. The pharmacokinetics of clarithromycin and its 14-hydroxy metabolite. J Hosp Infect 1991;19(suppl A):29-37.
29. Chu S-Y, Granneman GR, Pichotta RJ, Decourt JP, Girault J, Fourtillan JB. Effect of moderate or severe hepatic impairment of clarithromycin pharmacokinetics. J Clin Pharmacol 1993;33:480-5.
30. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 3rd ed. Villanova, PA: Author, 1993.
31. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, sixth information supplement (M100-S6). Villanova, PA: Author, 1995.
32. Bergman KL, Olsen KM, Peddicord TE, Fey PD, Rupp ME. Comparative study of activity and postantibiotic effect of physiologic levels of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin against clinical isolates of Haemophilus influenzae and Streptococcus pneumoniae. Pharmacotherapy 1998;18(2):432-33.
33. Craig WA. Postantibiotic effects and the dosing of macrolides, azalides, and streptogramins. In: Zinner SH, Young LS, Acar JF, Neu HC, eds. Expanding indications for the new macrolides, azalides, and streptogramins. New York: Marcel Dekker, 1997:27-38.
34. Busch U, Lechner U. Pharmacokinetic behavior of dirithromycin in human tissues [abstr]. In: Program and abstracts of the 28th interscience conference of antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1988.
35. Franschini F, Scaglione F, Pintucci G, Maccarinelli G, Dugnani S, Demartini G. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans J Antimicrob Chemother 1991;27(suppl A):61-5.
36. Benson JM, Arnold J, Manning SC, et al. Tonsillar tissue penetration of dirithromycin after multiple doses. J Clin Pharmacol 1996;36:832-7.
37. Muller-Serieys C, Bergogne-Berezin E, Lemaitre F. Kinetics of dirithromycin: concentrations in tonsils, bronchial mucosa, and secretions, multiple-dose studies. In: Zinner SH, Young LS, Acar JF, Neu HC, eds. Expanding indications for the new macrolides, azalides, and streptogramins. New York: Marcel Dekker, 1997:447-54.
38. Barza M. Tissue directed antibiotic therapy: antibiotic dynamics in cells and tissue. Challenges to antibiotic activity in tissue. Clin Infect Dis 1994;19:910-15.
39. Labro MT. Intracellular penetration of macrolides. Presse Medicale 1997;26(suppl 2):11-15.
40. Gerdes-Fange HF, Goetshi B, Rau M, et al. Comparative pharmacokinetics of dirithromycin and erythromycin in normal volunteers with special regard to accumulation in polymorphonuclear leukocytes and in saliva. Eur J Clin Pharmacol 1997;53:127-33.
41. Fuursted K, Knudsen JD, Peterson MB, Poulsen RL, Rehm D. Comparative study of bactericidal activities, postantibiotic effects, and effect of bacterial virulence of Pen G and six macrolides against Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41(4):781-4.
42. Quenzer RU, Guay DRP. Antimicrobial management strategies for patients with community acquired respiratory tract infections. Curr Ther Res 1995;56:466-77.
43. Fass RJ. Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analysis to compare in vitro activities and describe cross-resistance. Antimicrob Agents Chemother 1993;37:2080-6.
44. Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB. Comparative in vitro activities of 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother 1988;32:1710-19.
45. Ono T, Numata K, Nagate T, Mitsuhashi S, Inoue M. In vitro and in vivo antibacterial activities of clarithromycin. Chemotherapy 1996;42:159-69.
46. Kwon-Woon Y, Neu HC. In vitro activity of dirithromycin (LY 237216) compared with activities of other macrolide antibiotics. Antimicrob Agents Chemother 1990;34(9): 1839-42.
47. Hoogkamp-Korstanje JA, Dirks-Go SI, Kabel P, et al. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, coamoxiclav and sparfloxacin. J Antimicrob Chemother 1997;39(3):411-14.
48. Poulsen RL, Knudsen JD, Peterson MB, Fuursted K, Espersen F, Frimodt-Moller N. In vitro activity of six macrolides, clindamycin, and tetracycline on Streptococcus pneumoniae with different penicillin susceptibilities. APMIS 1996;104:227-33.
49. Barry AL, Pfaller MA, Euchs PC, Parker RR. In vitro activities of 12 orally administered antimicrobial agents against 4 species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrob Agents Chemother 1994;38:2419-25.
50. Brown SD, Burton P, Rich T. Susceptibility surveillance of U.S. respiratory pathogen isolates to newer macrolide and azalide antibiotics. Presented at the 94th general meeting of the American Society for Microbiology, Las Vegas, NV, May 23-27, 1994.
51. Bauerfeind A. In-vitro activity of dirithromycin in comparison with other established macrolides. J Antimicrob Chemother 1993;31(suppl C):39-49.
52. Waites K, Swiatlo E, Gray B, Brookings E. In vitro activities of oral antimicrobial agents against penicillin-resistant Streptococcus pneumoniae: implications for outpatient treatment. South Med J 1997;90(6):621-6.
53. Hamilton-Miller JMT. In vitro activities of 14-, 15-, and 16-membered macrolides against gram positive cocci. Antimicrob Agents Chemother 1992;29:141-7.
54. Felmingham D, Robbins MJ, Sanghrajka M, Leakey A, Ridgeway GL. In vitro activities of 14-, 15-, and 16-membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum. Drugs Exp Clin Res 1991;17:91-9.
55. Roblin PM, Kutlin A, Sokolovskaya N, Hammerslag MR. In vitro activity of dirithromycin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1997;39:647-9.
56. Johnson DM, Erwin ME, Barrett MS, Gooding BB, Jones RN. Antimicrobial activity of ten macrolide, linosamine and streptogramin drugs against Legionella species. Eur J Clin Microbiol Infect Dis 1992;11:751-5.
57. Welsh L, Gaydos C, Quinn TC. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. Antimicrob Agents Chemother 1996;40(1):212-14.
58. Hammerschlag MR, Qumei K, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992;36(7):1573-4.
59. Ishida K, Kaku M, Irifane K, et al. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994;38(4):790-8.
60. Rennie KA, Praad ES, Wenman WW. In vitro activity of dirithromycin against Mycoplasma species [abstr]. Presented al the 93rd general meeting of the American Society for Microbiology, Atlanta, GA, May 16-19, 1993
61. Grau E. Interaction between clarithromycin and oral anticoagulants. Ann Pharmacother 1996;30:1495-6.
62. Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH. Sufentanil disposition. Is it affected by erythromycin administration? Anaesthesiology 1993;78:260-5.
63. D'Arcy PF. Interactions with astemizole and terfenadine. Int Pharm J 1993;7:53.
64. Christiansen LQ, Bonde J, Kampmann JP. Drug interactions with intravenous and local anaesthetics. Acta Anaesth Scand 1994;38:15-29.
65. 2-blockers and antacids [abstr]. In: Program and abstracts of the 31st interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1991:185.
66. Nelson MV, Berchou RC, Kareti D, LeWitt PA. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin Pharmacol Ther 1990;47:694-7.
67. O'Conner NK, Fris J. Clarithromycin-carbamazepine interaction in a clinical setting. J Am Board Fam Pract 1994;7:489-92.
68. Albani F, Ravi R, Barazzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia 1993;34:161-2.
69. Richens AS, Chu SY, Sennello LT. Effect of multiple doses on the pharmacokinetics of carbamazepine [abstr]. In: Program and abstracts of the 30th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1990:213.
70. Sekkarie MA. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 1997;30(3):437-9.
71. Sadaba B, Lopez de Ocariz A, Azanza JR, Quiroga J, Cienfuegos JA. Concurrent clarithromycin and cyclosporin A treatment. J Antimicrob Chemother 1998;42:393-5.
72. Sketris IS, Wright MR, West ML. Possible role of the intestinal P-450 enzyme system in cyclosporine-clarithromycin interaction. Pharmacotherapy 1996;16:301-5.
73. Ferrari SL, Goffin E, Mouran M, Wallemacq P, Squifflet JP, Pirson Y. The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Transplantation 1994;58:725-7.
74. Treille S, Quoidbach A, Demol H, Vereerstraeten P, Abramowicz D. Kidney graft dysfunction after drug interaction between clarithromycin and cyclosporine. Nephrol Dial Transplanl 1996;11:1192-3.
75. Spicer ST, Liddle C, Chapman JR, et al. The mechanism of cyclosporine toxicity induced by clarithromycin. Br J Clin Pharmacol 1997;43(2):194-6.
76. Gillum JG, Bruzzese VL, Israel DS, Kaplowitz LG, Polk RE. Effect of clarithromycin on the pharmacokinetics of 2′,3′-dideoxyinosine in patients who are seropositive for human immunodeficiency virus. Clin Infect Dis 1996;22(4):716-18.
77. Taylor JW, Gammenthaler SA, Rape JM. Clarithromycin (Biaxin) induced digoxin toxicity [abstr]. Presented at the midyear clinical meeting of the American Society for Health-System Pharmacists, Miami, FL, December 4-8, 1994.
78. Ford A, Smith LC, Baltch AL, Smith RP. Clarithromycin induced digoxin toxicity in a patient with AIDS. Clin Infect Dis 1995;21:1051-2.
79. Midoneck SR, Etingin OR. Clarithromycin-related toxic effects of digoxin [letter]. N Engl J Med 1995;333:1505.
80. Brown BA, Wallace RJ, Griffin DE, Warden R. Clarithromycin associated digoxin toxicity in the elderly. Clin Infect Dis 1997;24:92-3.
81. Dobkin JF, Saha JR, Butler VP Jr, Neu HC, Lindenbaum J. Inactivation of digoxin by Eubacterium lentum, an anaerobe of human gut flora. Trans Assoc Am Physicians 1982;95:22-9.
82. Dobkin JF, Saha JR, Butler VP Jr, Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science 1983;220:325-7.
83. Bizjak ED, Mauro VF. Digoxin-macrolide drug interaction. Ann Pharmacother 1997;31:1077-9.
84. Navarskas JJ, Mcarthy DM, Spinler SA. Digoxin toxicity secondary to clarithromycin therapy. Ann Pharmacother 1997;31:864-6.
85. Laberge P, Martineau P. Clarithromycin-induced digoxin intoxication. Ann Pharmacother 1997;31:999-1002.
86. Paar D, Terjung B, Sauerbruch T. Life-threatening interaction between clarithromycin and disopyramide [letter]. Lancet 1997;349(9048):326-7
87. Horowitz RS, Dart RC, Gomez HF. Clinical ergotism with inguinal ischemia induced by clarithromycin-ergotamine interaction. Arch Intern Med 1996;156:456-8.
88. Boucharlat J, Franco A, Carpentier P, Charignon Y, Denis B, Hommel M. Ergotism in a psychiatric setting caused by combined dihydroergotamine-erythromycin propionate. Apropos of a case. Ann Med Psychol 1980;138(3):292-6.
89. Dette GA. Wechselwirkungen. In: Wiethoff EO, ed. Erythromycin-monographie. Wiesbaden: Wissenschaftliche Verlagsabteilung Deutsche Abbott, 1986:3.1-3.16.
90. Gustavson LE, Shi H, Palmer RN, Seipman NC, Craft JC. Drug interaction between clarithromycin and fluconazole in healthy subjects [abstr]. Clin Pharmacol Ther 1996;59:185.
91. Amsden GW, Cheng KL, Nafziger AN, Peloquin CA. Cimetidine (CIM) prolongs clarithromycin (CLAR) absorption. In: Program and abstracts of the 4th international conference on the macrolides, azalides, streptogramins, and ketolides. Atlanta, GA: Wallace Communications, 1998.
92. Cheng KL, Nafziger AN, Peloquin CA, Amsden GW. Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrob Agents Chemother 1998;42(4):927-9.
93. Brion N, Kollenbach K, Marion MH, Gregoire A, Advenier C, Pays M. Effect of macrolide (spiramycin) on pharmacokinetics of L-dopa and carbidopa in healthy volunteers. Clin Neuropharmacol 1992;15:229-35.
94. Carr RA, Edmonds A, Shi H, et al. Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. Antimicrob Agent Chemother 1998;42(5):1176-80.
95. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis [letter]. Ann Intern Med 1988;109:682-3.
96. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use - report of two cases in cardiac transplant recipients. JAMA 1988;260:239-41.
97. Spach DH, Bauwens JE, Clark CD. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991;154:213-15.
98. Grunden JW, Fisher KA. Lovastalin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother 1997;31(7-8):859-63.
99. Roschal S, Moy J, Richmond GW. Steroid enhancing effects of clarithromycin [abstr]. J Allergy Clin Immunol 1996;97(pt 3):253.
100. Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, DeBartolo ML, Schneck DW. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995;39:2078-83.
101. von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995;13(2):105-22.
102. Baldit G, Vincon G, Bistue C, Albin H. Influence of a new macrolide antibiotic, dirithromycin, on antipyrine clearance [in French]. Therapie 1987;42:263-6.
103. Bachmann K, Schwartz JI, Fornay R Sr, Frogameni A, Jauregui LE. Single dose phenytoin clearance during erythromycin treatment. Res Commun Chem Pathol Pharmacol 1984;4:207-17.
104. Burger DM, Meenhorst PL, Muldler JW, et al. Therapeutic drug monitoring of phenytoin in patients with acquired immunodeficiency syndrome. Ther Drug Monit 1994;16:616-20.
105. Al-Humayyd MS. Pharmacokinetic interactions between erythromycin, clarithromycin, roxithromycin and phenytoin in the rat. Chemotherapy 1997;43(2):77-85.
106. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-intracellulare infection. J Infect Dis 1995;171:747-50.
107. Griffin DE, Brown BA, Girard WM, Murphy DT. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Invest Dis 1995;21:594-8.
108. Oullet D, Hsu A, Granneman GR, et al. Assessment of the interaction between ritonavir (R) and clarithromycin (C) [abstr]. Clin Pharmacol Ther 1996;59:143.
109. Honig PK, Wortham DC, Zamani K, Catinena LR. Comparison of the effect of macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994;7:148-56.
110. Gillum JG, Israel DS, Scott RB, Climo MW, Polk RE. Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 1996;40(7):1715-16.
111. Siepman N. Influence of clarithromycin on theophylline levels in patients with bronchial secretions. Presented at the 1st annual conference on macrolides, azalides, and streptogramins, Sante Fe, NM, Jan 22-25, 1992.
112. Yeates RA, Zimmerman T, Laufen H. Influence of the antibiotics clarithromycin and azithromycin on the pharmacokinetics of midazolam. Presented as a poster at the 3rd international conference on the macrolides, azalides, and streptogramins, Lisbon, Portugal, January 1996.
113. Phillips JP, Antal EJ, Smith RB. A pharmacokinetic drug interaction between erythromycin and triazolam. J Psychopharmacol 1986;6:297-9.
114. Warot D, Bergougman L, Lamiable D, et al. Troleandomycintriazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. Eur J Clin Pharmacol 1987,32:389-93.
115. Gascon MP, Dayer P, Uhlvogel F. Les interactions medicamenteuse du midazolam. Schweiz Med Wochenschr 1989;119:1834-6.
116. Okkola KT, Arano K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
117. Wood M. Midazolam and erythromycin. Br J Anaesth 1991;67:131.
118. Hiller A, Olkkola KT, Isohanni P. Unconsciousness associated with midazolam and erythromycin. Br J Anaesth 1990;65.826-8.
119. Narchi P, Benhumou D, Elhandoury M. Interactions of preoperative erythromycin administration with general anaesthesia. Can J Anaesth 1993;40:444-7.
120. Redington K, Well C, Petito P. Erythromycin and valproate interaction. Ann Intern Med 1992;116:877-8.
121. Grau E, Gontcuberta J, Felez J. Erythromycin-oral anticoagulation interactions. Arch Intern Med 1986;146:1639.
122. Bartle WR. Possible warfarin-erythromycin interaction. Arch Intern Med 1980;140:985-7.
123. Husserl FE. Erythromycin-warfarin interaction. Arch Intern Med 1983;143:1831-6.
124. Recker MW, Kier KL. Potential interaction between clarithromycin and warfarin. Ann Pharmacother 1997;31(9):996-8.
125. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23(4):685-93.
126. Polis MA, Piscitelli SC, Vogel S, et al. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997;41(8):1709-14.
127. Vance E, Watso-Bitar M, Gustavson L, Kazanjian P. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob Agents Chemother 1995;39:1355-60.
128. Muller O. Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother 1993;31(suppl E):137-46.
129. Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 1993;31(suppl E):153-62.
130. Karma P, Pukander J, Penttila M, et al. The comparative efficacy and safety of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis. J Antimicrob Chemother 1991;27(suppl A):83-90.
131. Bachand RT. Comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1991;27(suppl A):91-100.
132. Howie VM. Eradication of bacterial pathogens from middle ear infections. Clin Infect Dis 1992;14(suppl 2):209-10.
133. Pozzi E, Grossi E, Pecori A, et al. Azithromycin versus clarithromycin in the treatment of acute exacerbations of chronic bronchitis. Curr Ther Res 1994;55(7):759-64.
134. Hosie J, Quinn P, Smits P, Sides G. A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother 1995;36:173-83.
135. Le Royer C, Boussac J, Lode H. A comparison of 5 days of dirithromycin (500 mg once daily) and 7 days of and 7 days of roxithromycin (150 mg twice daily) in acute bacterial exacerbations of chronic bronchitis. Data on file, Eli Lilly, Indianapolis, IN.
136. Pozzi E. Clinical efficacy of dirithromycin versus miocamycin in the treatment of acute bronchitis or acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1993;31(suppl C):153-8.
137. Liippo K, Tala E, Puolijoki H, Bruckner OJ, Rodrig J, Smits JP. A comparative study of dirithromycin and erythromycin in bacterial pneumonia. J Infect 1994;28:131-9.
138. Sides GD. Clinical efficacy of dirithromycin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1993;31(suppl C):131-8.
139. Jacobson K. Clinical efficacy of dirithromycin in pneumonia. J Antimicrob Chemother 1993;31(suppl C):121-9.
140. Gaillat J. A multicentre study comparing the safety and efficacy of dirithromycin in the treatment of bronchitis. J Antimicrob Chemother 1993;31(suppl C):139-51.
141. Fong IW, Laforge J, Dubois J, Small D, Grossman R, Zakhari R. Clarithromycin versus cefaclor in lower respiratory tract infections. Clin Invest Med 1995;18:131-8.
142. Wettengel R, Vetter N, Waardenburg FA. Clarithromycin versus cefaclor for the treatment of mild to moderate acute bacterial bronchitis. J Antimicrob Chemother 1993;31:963-72.
143. Neu C, Chick TW. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest 1993;104:1393-9.
144. Notario G, Siepman N, Devcich K, Guay DRP. Comparative safety and efficacy of clarithromycin and three oral cephalosporins in the treatment of outpatients with bacterial bronchitis. Curr Ther Res 1993;54(6):628-40.
145. Aldons PM. A comparison of clarithromycin with ampicillin in the treatment of patients with acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother 1991;27(suppl A):101-8.
146. Guay DRP, Craft JC. Comparative safety and efficacy of clarithromycin and ampicillin in the treatment of out-patients with acute exacerbation of chronic bronchitis. J Intern Med 1992;231:295-301.
147. Chien SM, Pichotta P, Siepman N, Chan CK. Treatment of community acquired pneumonia: a multicenter, double-blind, randomized study comparing clarithromycin and erythromycin. Chest 1993;103:697-701.
148. Anderson G, Esmonde TS, Coles S, Macklin J, Carnegie C. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community acquired pneumonia. J Antimicrob Chemother 1991;27(suppl A):117-24.
149. Cassell GH, Drnec J, Waites KB, et al. Efficacy of clarithromycin against Mycoplasma pneumoniae. J Antimicrob Chemother 1991;27(suppl A):47-59.
150. Straneo G, Scarpazza G. Efficacy and safety of clarithromycin versus josamycin in the treatment of hospitalized patients with bacterial pneumonia. J Int Med Res 1990;18:164-70.
151. Poirier R. Comparative study of clarithromycin and roxithromycin in the treatment of community acquired pneumonia. J Antimicrob Chemother 1991;27(suppl A):109-16.
152. Sides GD, Conforti PM. Safety profile of dirithromycin. J Antimicrob Chemother 1993;31(suppl C):175-85.
153. Hardy DJ, Guay DRP, Jones RN. Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview. Diagn Microbiol Infect Dis 1992;15;39-53.
154. Derriennic M, Conforti PM, Sides GD. Dirithromycin in the treatment of streptococcal pharyngitis. J Antimicrob Chemother 1993;31(suppl C):89-95.
155. Craft JC, Srepman N. Overview of the safety profile of clarithromycin suspension in pediatric patients. Pediatr Infect Dis J 1993;12(suppl 3):S142-7.
156. Ruggiero G, Utili R, Adinolfi LE, et al. Clinical efficacy of dirithromycin versus miocamycin in tonsillopharyngitis. J Antimicrob Chemother 1993;31(suppl C):103-9.
157. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991;91(suppl 3A):40S-5.
158. Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993;16(3):215-21.
159. Kuder HV. Propionyl erythromycin. A review of 20,252 case reports for side effect data. Clin Pharmacol Ther 1960;1:604-9.
160. O'Neil SJ, Millar ED, Coles SJ, Bachand RT. Safety and efficacy of clarithromycin in the treatment of acute mild to moderate respiratory tract infections. Ir Med J 1991;84:33-5.
161. Periti P, Mazzei T, Mini E, Novelli A. Adverse effects of macrolide antibiotics. Drug Saf 1993;9(5):346-64.
162. Franklin MR. Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic intermediate complexes. Pharmacol Ther 1977;2:227-45.
163. Viluksela M, Vainio PJ, Tuominen RK. Cytotoxicity of macrolide antibiotics in cultured human liver cell line. J Antimicrob Chemother 1996;38:465-73.
164. Schlegel PN, Chang TSK, Marshall FF. Antibiotics; potential hazards to male fertility. Fertil Steril 1991;55:235-42.
165. Sanofi Pharmaceutical, Inc. Dirithromycin prescribing information. New York, NY;December 22, 1997.
166. Lindstrom TD, Hanssen BR, Wrighton SA. Cytochrome P-450 complex Formation by dirithromycin and other macrolides in rat and human livers. Antimicrob Agents Chemother 1997;37(2):265-9.
167. Franklin MR. Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol 1991;206:559-73.
168. Larrey D, Funck-Bretano C, Breil P, et al. Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol 1983;32:1063-8
169. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
170. Rodrigues AD, Roberts EM, Mulford DJ, et al. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 1997;25(5):623-30.
171. Ohmori S, Ishii I, Kuriya S-I, et al. Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats. Drug Metab Dispos 1993;21: 358-63.
172. Tinel M, Descatoire V, Larrey D, et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 1989;250:746-51.
173. Wrighton SA, Ring BJ. Examination of the in vitro potential of dirithromycin, erythromycylamine, and erythromycin to inhibit CYP3A metabolism. Data on file. Eli Lilly and Co., Indianapolis, IN.
174. Bachmann K, Sullivan TJ, Reese JH, et al. The influence of dirithromycin on the pharmacokinetics of cyclosporine in healthy subjects and in renal transplant patients. Am J Ther 1995;2:490-8.
175. Bachmann K, Sullivan TJ, Reese JH, et al. The pharmacokinetics of oral cyclosporin A are not affected by dirithromycin. Data on file. Eli Lilly and Co., Indianapolis, IN.
176. Wermeling DP, Chandler MH, Sides GD, Collins D, Muse KN. Dirithromycin increases ethinyl estradiol clearance without allowing ovulation. Obstet Gynecol 1995;86:78-84.
177. McConnell SA, Nafziger AN, Amsden GW. Lack of effect of oral dirithromycin (DIR) on the pharmacokinetics of oral theophylline (THEO) in healthy volunteers. In: Program and abstracts of the annual meeting of the American College of Clinical Pharmacy, Cincinnati, OH, November 8-11, 1998.
178. Bachmann K, Jauregui L, Sides GD, Sullivan LT. Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin. J Clin Pharmacol 1993;33:861-5.
179. Bachmann K, Nunlee M, Martin M, et al. Changes in steady-state pharmacokinetics of theophylline during treatment with dirithromycin. J Clin Pharmacol 1990;30:1001-5.
180. Ellsworth A, Horn JR, Wilkinson W, Black DJ, Church L. An evaluation of the effect of dirithromycin (D) and erythromycin (E) on the pharmacokinetics of warfarin (W) [abstr]. Presented at the 35th interscience conference on antimicrobial agents and chemotherapy, San Francisco, September 17-20, 1995.
181. Anastasio GD, Little JM Jr, Robinson MD, Pettice YL, Leicht BB, Horton HJ. Impact of compliance and side effects on the clinical outcome of patients treated with oral erythromycin. Pharmacotherapy 1994;14(2):229-34.